Adverse Events Clinical Trial
— HOPESOfficial title:
A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely
NCT number | NCT01291667 |
Other study ID # | HOPES |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | February 6, 2011 |
Last updated | February 7, 2011 |
Start date | May 2009 |
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.
Status | Completed |
Enrollment | 330 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - signed ICF - pathologic diagnosis breast cancer - HER2+ status defined as IHC3+ Staining or in situ hybridization positive at least 1 measurable lesion as per RECIST criteria age from 18y to 70y KPS>=70 Exclusion Criteria: - More than three prior chemotherapy lines for advanced disease LVEF<50% - prior exposure vinorebine for breast cancer - prior exposure Trastuzumab for breast cancer - uncontrolled brain metastasis - breastfeeding or pregnant |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Shanghai CP Guojian Pharmaceutical Co.,Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progress-free survival | |||
Secondary | overall response rate,safety |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05390125 -
Effectiveness of a Proficiency-based Progression Communication Training Programme
|
||
Completed |
NCT04012320 -
Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
|
||
Completed |
NCT02268331 -
Comparison of Active vs. Passive Surveillance to Collect Adverse Events
|
N/A | |
Completed |
NCT00244673 -
Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination
|
Phase 4 | |
Recruiting |
NCT05038527 -
ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery
|
N/A | |
Completed |
NCT00681395 -
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
|
Phase 1 | |
Completed |
NCT05359666 -
Retrospective Independent Safety Review of Closed Irrisept Study
|
N/A | |
Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05310344 -
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
Completed |
NCT05815615 -
Plasmapheresis: a Multi-modal Approach
|
N/A | |
Completed |
NCT02130570 -
Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions
|
N/A | |
Recruiting |
NCT05804188 -
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
|
||
Not yet recruiting |
NCT06117176 -
Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III
|
||
Recruiting |
NCT02725073 -
Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT02928705 -
Quality of Telemedically Guided Prehospital Analgesia
|
N/A | |
Withdrawn |
NCT01128127 -
Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs)
|
N/A | |
Terminated |
NCT02011607 -
Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia
|
||
Completed |
NCT02310815 -
ReSure Sealant Post Approval Study
|
N/A | |
Recruiting |
NCT05709392 -
Preterm DElayed Cord Clamping and Early Skin-to-Skin Contact: PreDECESS
|
N/A |